AbbVieABBV
ABBV
About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Employees: 50,000
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 16 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
107% more first-time investments, than exits
New positions opened: 240 | Existing positions closed: 116
27% more call options, than puts
Call options by funds: $3.65B | Put options by funds: $2.87B
18% more funds holding in top 10
Funds holding in top 10: 174 [Q2] → 206 (+32) [Q3]
10% more capital invested
Capital invested by funds: $225B [Q2] → $246B (+$21.4B) [Q3]
4% more funds holding
Funds holding: 3,296 [Q2] → 3,420 (+124) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 1,378 | Existing positions reduced: 1,376
3.31% less ownership
Funds ownership: 73.79% [Q2] → 70.48% (-3.31%) [Q3]
Research analyst outlook
16 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$191
9%
upside
Avg. target
$210
19%
upside
High target
$225
28%
upside
16 analyst ratings
12 positive
75%
4 neutral
25%
0 negative
0%
Piper Sandler Christopher Raymond 19% 1-year accuracy 5 / 27 met price target | 25%upside $220 | Overweight Maintained | 17 Dec 2024 |
B of A Securities Tim Anderson 50% 1-year accuracy 3 / 6 met price target | 9%upside $191 | Neutral Reinstated | 10 Dec 2024 |
Leerink Partners David Risinger 33% 1-year accuracy 3 / 9 met price target | 17%upside $206 | Outperform Upgraded | 22 Nov 2024 |
Wolfe Research Alexandria Hammond 33% 1-year accuracy 3 / 9 met price target | 17%upside $205 | Outperform Initiated | 15 Nov 2024 |
JP Morgan Chris Schott 24% 1-year accuracy 4 / 17 met price target | 14%upside $200 | Overweight Maintained | 13 Nov 2024 |
Financial journalist opinion
Based on 54 articles about ABBV published over the past 30 days
Positive
The Motley Fool
13 hours ago
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring something for investors, too?
Positive
Seeking Alpha
2 days ago
Retirement-Ready Income: 5 Dividend Gems I'd Buy If I Were 65
Dividend investing can provide reliable income and peace of mind in retirement. I share five standout picks perfect for a retirement-ready portfolio. These stocks offer strong yields, consistent growth, and robust fundamentals, making them ideal for retirees seeking steady cash flow and stability. Whether you're planning for retirement or already there, these dividend gems combine reliability and long-term potential to help secure your financial future.
Positive
The Motley Fool
2 days ago
2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond
What will be the hottest investing trend on Wall Street next year? Maybe artificial intelligence will keep up its momentum, or perhaps interest in weight loss-focused pharmaceutical companies will increase.
Positive
Zacks Investment Research
3 days ago
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Positive
Seeking Alpha
3 days ago
My Dividend Stock Portfolio: New November Dividend Record - 97 Holdings With 18 Buys
In November, I invested $1,400 primarily in Business Development Companies, boosting my yearly dividend income by $148, with a YTD total exceeding $1,400. My portfolio achieved all-time highs, driven by a strong earnings season and a dovish Fed, with BDCs like Goldman Sachs BDC and Blackstone Secured Lending Fund as key picks. November's dividend income hit a record $620, a 20% Y/Y growth, mainly due to ongoing investments into Hercules Capital.
Neutral
Business Wire
3 days ago
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo; Topic is Pharmacokinetics of AL001.
Positive
Zacks Investment Research
4 days ago
4 Big Drug Stocks That May Continue to Outperform in 2025
Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025.
Positive
Benzinga
4 days ago
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Neutral
Investors Business Daily
4 days ago
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
AbbVie has a lofty goal for 2025 — and a big move in cancer treatment could stoke beleaguered AbbVie stock. The post AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth.
Neutral
Zacks Investment Research
5 days ago
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
In the most recent trading session, AbbVie (ABBV) closed at $171.63, indicating a -1% shift from the previous trading day.
Charts implemented using Lightweight Charts™